Search in:

Advanced search

Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 1

Submit an article Journal homepage

415

Views

CrossRef citations to date

Altmetric

Reviews

Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression

Anke Kretz-Rommel Aracari Biotech, Del Mar, CA, USA +1 619 823 0368; +1 858 350 7484; [email protected]

, PhD &

Katherine S Bowdish Aracari Biotech, Del Mar, CA, USA +1 619 823 0368; +1 858 350 7484; [email protected]

Pages 5-15 | Published online: 17 Dec 2007

Cite this article
https://doi.org/10.1517/14712598.8.1.5

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Mcwhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006;103:1041-6
PubMed Web of Science ®Google Scholar
Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-7
PubMed Web of Science ®Google Scholar
Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-8
PubMed Web of Science ®Google Scholar
Boon T, Coulie PG, Van Den EB. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8
PubMedGoogle Scholar
Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-36
PubMed Web of Science ®Google Scholar
Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
PubMed Web of Science ®Google Scholar
Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74
PubMed Web of Science ®Google Scholar
Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007;13:S727-32
PubMed Web of Science ®Google Scholar
Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005;12:1005-16
PubMed Web of Science ®Google Scholar
Barclay AN, Ward HA. Purification and chemical characterisation of membrane glycoproteins from rat thymocytes and brain, recognised by monoclonal antibody MRC OX 2. Eur J Biochem 1982;129:447-58
PubMedGoogle Scholar
Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001;102:173-9
PubMed Web of Science ®Google Scholar
Clark MJ, Gagnon J, Williams AF, Barclay AN. MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain. EMBO J 1985;4:113-18
PubMed Web of Science ®Google Scholar
Barclay AN, Clark MJ, Mccaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986;51:149-57
PubMedGoogle Scholar
Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002;23:285-90
PubMed Web of Science ®Google Scholar
Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-71
PubMed Web of Science ®Google Scholar
Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002;161:1669-77
PubMed Web of Science ®Google Scholar
Rosenblum MD, Olasz EB, Yancey KB, et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol 2004;123:880-7
PubMed Web of Science ®Google Scholar
Gorczynski RM, Chen Z, Yu K, Hu J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol 2001;101:328-34
PubMed Web of Science ®Google Scholar
Clark DA, Yu G, Levy GA, Gorczynski RM. Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. Semin Immunol 2001;13:255-63
PubMed Web of Science ®Google Scholar
Gorczynski RM. Evidence for an immunoregulatory role of OX2 with its counter ligand (OX2L) in the regulation of transplant rejection, fetal loss, autoimmunity and tumor growth. Arch Immunol Ther Exp (Warsz) 2001;49:303-9
PubMed Web of Science ®Google Scholar
Gorczynski RM, Chen Z, Lee L, Yu K, Hu J. Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol 2002;104:256-64
PubMed Web of Science ®Google Scholar
Copland DA, Calder CJ, Raveney BJ, et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007;171:580-8
PubMed Web of Science ®Google Scholar
Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol 2004;78:7667-76
PubMed Web of Science ®Google Scholar
Zhang J, Wang J, Wood C, Xu D, Zhang L. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J Virol 2005;79:5640-52
PubMed Web of Science ®Google Scholar
Shiratori I, Yamaguchi M, Suzukawa M, et al. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol 2005;175:4441-9
PubMed Web of Science ®Google Scholar
Cameron CM, Barrett JW, Liu L, Lucas AR, McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo J Virol 2005;79:6052-67
PubMed Web of Science ®Google Scholar
Voigt S, Sandford GR, Hayward GS, Burns WH. The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht. J Gen Virol 2005;86:263-74
PubMed Web of Science ®Google Scholar
Langlais CL, Jones JM, Estep RD, Wong SW. Rhesus rhadinovirus R15 encodes a functional homologue of human CD200. J Virol 2006;80:3098-103
PubMed Web of Science ®Google Scholar
Gorczynski RM, Cattral MS, Chen Z, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 1999;163:1654-60
PubMed Web of Science ®Google Scholar
Ragheb R, Abrahams S, Beecroft R, et al. Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2. Immunol Lett 1999;68:311-15
PubMed Web of Science ®Google Scholar
Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L. Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 2004;77:1138-44
PubMed Web of Science ®Google Scholar
Fallarino F, Sselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004;173:3748-54
PubMed Web of Science ®Google Scholar
Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+ CD25+Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:488-91
PubMed Web of Science ®Google Scholar
Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004;173:6786-93
PubMed Web of Science ®Google Scholar
Cherwinski HM, Murphy CA, Joyce BL, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005;174:1348-56
PubMed Web of Science ®Google Scholar
Bennett FL, Rawstron AC, O'Connor SJM, et al. Increased expression of CD200 antigen, a potential immunotherapeutic target, is consistently found in CLL cells irrespective of biological features. 108 Edition; 2006
Google Scholar
Siva A, Xin H, Qin F, et al. Immune evasion by melanoma and ovarian tumor cells through upregulation of the immunosuppressive molecule CD200. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006;24(18S):2545
Google Scholar
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
PubMed Web of Science ®Google Scholar
Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81
PubMed Web of Science ®Google Scholar
html SEER Stat Fact Sheet on Chronic Lymphocytic Leukaemia Available at: URL:http://seer.cancer.gov/statfacts/html/clyl [last accessed November 2007]
Google Scholar
Catovsky D. Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2004;18:783-94, vii
PubMed Web of Science ®Google Scholar
Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am 2004;18:827-48, viii
PubMed Web of Science ®Google Scholar
Mertens D, Wolf S, Schroeter P, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 2002;99:4116-21
PubMed Web of Science ®Google Scholar
Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16
PubMed Web of Science ®Google Scholar
Wong KF, So CC. Chronic lymphocytic leukemia with a novel der(8;15)(q10;q10) translocation. Cancer Genet Cytogenet 2002;132:159-60
PubMed Web of Science ®Google Scholar
Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003;88:31-8
PubMed Web of Science ®Google Scholar
Mccaughan GW, Clark MJ, Hurst J, Grosveld F, Barclay AN. The gene for MRC OX-2 membrane glycoprotein is localized on human chromosome 3. Immunogenetics 1987;25:133-5
PubMed Web of Science ®Google Scholar
Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75
PubMed Web of Science ®Google Scholar
Schulz H, Klein SK, Rehwald U, et al. Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-20
PubMed Web of Science ®Google Scholar
Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
PubMed Web of Science ®Google Scholar
Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
PubMed Web of Science ®Google Scholar
Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9
PubMed Web of Science ®Google Scholar
Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62
PubMed Web of Science ®Google Scholar
Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Haematol Oncol Clin North Am 2004;18(4):915-26, x
PubMed Web of Science ®Google Scholar
Freedman LR, Cerottini JC, Brunner KT. In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 1972;109:1371-8
PubMed Web of Science ®Google Scholar
Bevan MJ, Cohn M. Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 1975;114:559-65
PubMed Web of Science ®Google Scholar
Chattopadhyay S, Chakraborty NG. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 2005;66:884-91
PubMed Web of Science ®Google Scholar
Tendler CL, Burton JD, Jaffe J, et al. Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 1994;54:4430-5
PubMed Web of Science ®Google Scholar
Takeuchi T, Ueki T, Sasaki Y, et al. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 1997;43:375-81
PubMed Web of Science ®Google Scholar
Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 2000;44:271-4
PubMed Web of Science ®Google Scholar
Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002;49:159-66
PubMed Web of Science ®Google Scholar
Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 1999;177:203-8
PubMed Web of Science ®Google Scholar
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28
PubMed Web of Science ®Google Scholar
Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol (In Press)
Google Scholar
Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007;178:5595-605
PubMed Web of Science ®Google Scholar
Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-91
PubMed Web of Science ®Google Scholar
Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993;178:661-7
PubMed Web of Science ®Google Scholar
Mueller JP, Giannoni MA, Hartman SL, et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 1997;34:441-52
PubMed Web of Science ®Google Scholar
Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9
PubMed Web of Science ®Google Scholar
Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65
PubMed Web of Science ®Google Scholar
Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8
PubMed Web of Science ®Google Scholar
Gorczynski RM, Chen Z, Clark DA, et al. Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 2004;52:147-63
PubMed Web of Science ®Google Scholar
Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966;37:547-59
PubMed Web of Science ®Google Scholar
Klein G, Dombos L, Gothoskar B. Sensitivity of Epstein–Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer 1972;10:44-57
PubMed Web of Science ®Google Scholar
Hami LS, Green C, Leshinsky N, Markham E, Miller K, Craig S. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 2004;6:554-62
PubMed Web of Science ®Google Scholar
Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72
PubMed Web of Science ®Google Scholar
Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin Exp Immunol 2001;126:16-28
PubMed Web of Science ®Google Scholar
Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 2003;9:1656-65
PubMed Web of Science ®Google Scholar
Takahashi T, Tanaka Y, Nieda M, et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 2003;27:795-802
PubMed Web of Science ®Google Scholar
Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 2003;63:4497-506
PubMed Web of Science ®Google Scholar
Caligaris-Cappio F, De Leo AM, Bertero MT. Autoimmune phenomena and hepatitis C virus in lymphoproliferative and connective tissue disorders. Leuk Lymphoma 1997;28:57-63
PubMed Web of Science ®Google Scholar
Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1689-92
PubMed Web of Science ®Google Scholar
Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003;30:483-92
PubMed Web of Science ®Google Scholar
Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patient with chronic lymphocytic leukemia after therapy with fludarabine 2. Blood 2005;106:2018-25
PubMed Web of Science ®Google Scholar
Sinkovics JG, Horvath JC. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol 2006;29:765-77
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date